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Abstract
Current antibiotics effectiveness relies on higher doses and administration frequency, which are responsible for the 
growth of antimicrobial resistance (AMR). AMR is one of the major threatening issues of the century with last-line anti-
biotics already failing. To overcome such problems associated with bacterial infections, nanoparticles combined with 
antibiotics emerged as a promising strategy. In this work, nanocarriers comprising of gold–silica core–shell mesoporous 
nanoparticles (Au@MNs) and silica mesoporous nanoparticles (MNs) were synthesized, loaded with amoxicillin (Amox) 
and ofloxacin and investigated regarding its antibacterial activity towards S. aureus, methicillin-resistant S. aureus (MRSA), 
E. coli and P. aeruginosa. Both nanocarriers showed a beneficial role in the effective delivery of amoxicillin against MRSA 
and the well-known β-lactam resistant P. aeruginosa. Reductions of 10-fold (Amox@MNs) and 20-fold (Amox@Au@MNs) 
in the amount of antibiotic to treat P. aeruginosa; and a reduction of 20-fold (Amox@MNs) towards MRSA allied to a full 
reversion of resistance, strongly supports the promising potential of these nanocarriers to tackle antibiotics resistance.
Keywords Mesoporous silica nanoparticles · Amoxicillin · Ofloxacin · Antimicrobial resistance · Bacteria · Gold 
nanoparticles
1 Introduction
The inappropriate administration of antibiotics and their 
relative non-specificity are responsible for bacterial infec-
tions treatment’s ineffectiveness and for the growth of 
antimicrobial resistance [1, 2]. Recent studies presented 
by the European Food Safety Authority (EFSA) and by 
the European Centre for Disease Prevention and Control 
(ECDC) conducted in the 28 European member states 
revealed an increased resistance to antibiotics in the Sal-
monella, Escherichia coli and Staphylococcus aureus bac-
teria strains [2, 3]. As a consequence, current antibiotics 
effectiveness relies on higher drug doses and administra-
tion frequency, which in turn favour the emergence of new 
resistant bacteria [3]. To overcome this issue, the produc-
tion of novel antibiotics has been proposed as a solution. 
However, with time these drugs will cease to be effective, 
as well. The resolution should focus then on the increase 
of the durability and effectiveness of existing drugs and 
not in the design of new ones [3].
The implementation of nanoparticles as antibacterial 
agents appears to be a very promising strategy to over-
come such problems associated with bacterial infec-
tions. Toxicity reduction, drug solubility enhancement, 
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controlled release of multiple drugs, lower antibiotic dos-
age, resistance overcoming and lower costs are some of 
the advantages reported by the use of the nanomaterials, 
compared with conventional antibiotics [4, 5].
Regarding antibacterial nanomaterials, inorganic nan-
oparticles containing silver, gold, copper oxide, titanium 
oxide, and cerium oxide nanoparticles have been found 
to have potent antibacterial effects [6–9]. It has been pro-
posed that these materials can exert antibacterial activ-
ity through multiple modes of action, such as metal ions 
release, non-oxidative and oxidative stress, leading to mul-
tiple gene mutations in the bacterial cell and consequently 
inhibiting bacteria from acquiring resistance against nano-
particles [10].
Among all nanomaterials, mesoporous silica nanopar-
ticles (MNs), are very promising for pharmaceutical use, 
mainly due to their multiple design options, providing 
different strategies to combat bacterial infections [11]. 
MNs have a high surface area and pore volume with a 
large loading capacity to combat bacterial infection in 
all stages (prevention, detection and treatment). Several 
studies showed that loading antibiotics onto MNs induces 
an improvement in the effectiveness of the drug [3, 12, 13]. 
Moreover, the combination of MNs with other metals (cop-
per, zinc, silver, gold) can bring an added value in bacterial 
eradication [14, 15].
As an example, Zink et al. [16] reported the antibacte-
rial effect of silver nanocrystal into MNs against E. coli and 
Bacillus anthracis, showing efficiency against B. anthracis 
in the smallest tested concentration (20 μg/mL). A more 
sophisticated system was published by Zhou et al. [17] 
where chlorhexidine (CHX) was loaded into silver@MNs 
and tested against S. aureus and E. coli. In both bacteria, 
the CHX@silver@MNs system showed a synergistic bacte-
ricidal effect higher than  AgNO3 and CHX separately, with 
a minimum inhibitory concentration (MIC) and minimum 
bactericidal concentration (MBC) of 25 μg/mL and 12.5 μg/
mL for S. aureus and E. coli, respectively.
Silver core-mesoporous silica nanoparticles loaded with 
ofloxacin (AgMNs@oflox) were also tested with S. aureus 
and E. coli. A synergetic effect was observed, being the 
best antibacterial results obtained for AgMNs@oflox for 
the strain S. aureus ATCC 25923, with MIC and MIB values 
of 5 μg/mL and 25 μg/mL [18].
Other metal ions, especially the mesoporous silica 
copper and nickel-supported nanoparticles, MNs-Schiff 
base (SB)-Cu and MNs-SB-Ni, presented a bactericidal 
and bacteriostatic effect against S. aureus and E. coli [19]. 
However, gold nanoparticles’ inexistent toxicity towards 
living organisms (prokaryotic and eukaryotic), as well as 
their known photothermal behaviour, make gold-based 
systems viable and biocompatible building blocks for 
complex nanostructures of biological application, namely 
their possible conjugation with antibacterial agents for the 
application in living eukaryotic systems.
Thus, in this work we present the synthesis of core–shell 
gold–silica based mesoporous silica nanoparticles for the 
effective delivery of ofloxacin and amoxicillin towards 
Staphylococcus aureus, methicillin-resistant Staphylococ-
cus aureus (MRSA), Escherichia coli and Pseudomonas aer-
uginosa. Synergetic effects and drug delivery efficiency 
between the antibiotics and nanoparticles will also be 
studied, aiming for a significant decrease of administered 
antibiotic, while maintaining bactericidal performance.
2  Materials and methods
Hydrogen tetrachloroaurate(III) hydrate  (HAuCl4, 99%), 
sodium citrate tribasic, ethylene glycol (EG) hexadecyl-
trimethylammonium bromide (CTAB, ≥ 98%), ammonium 
nitrate, amoxicillin, ofloxacin, ethanol (EtOH) and metha-
nol (MeOH) were used as purchased from Sigma-Aldrich. 
Tetraethyl orthosilicate (TEOS, 99.999%), sodium hydrox-
ide (NaOH) and sodium chloride (NaCl, 99%) were bought 
from Alfa Aesar and PanReact, respectively. Dimethyl sul-
foxide (DMSO) was acquired from CarloErba. All reagents 
were used as bought and all solutions unless otherwise 
indicated, were prepared in deionised (DI) MiliQ water. 
Antibacterial assays were performed against gram-nega-
tive Escherichia coli ATCC ® 8739™ (E. coli) and Pseudomonas 
aeruginosa ATCC ® 9027™ (P. aeruginosa), and gram-positive 
bacteria Staphylococcus aureus ATCC ® 6538™ (S. aureus), 
methicillin-resistant Staphylococcus aureus ATCC ® 33591™ 
(MRSA). Muller Hinton Agar (MHA), Muller Hinton Broth 
(MHB) and Trypto Casein-Soy Agar (TSA) were obtained 
from Biokar Diagnostics (Allonne, France).
2.1  Instrumentation
Gold concentration was obtained, at 267 nm, by Induc-
tively Coupled Plasma—Atomic Emission Spectrometer 
(ICP-AES, Horiba Jobin–Yvon), equipped with a 40.68 MHz 
RF generator, Czerny-Turner monochromator with 1.00 m 
(sequential), autosampler AS500 and CMA (Concomitant 
Metals Analyzer), from REQUIMTE Laboratory of Analysis 
from FCT-UNL (Portugal). UV–Vis absorption spectra were 
acquired on a Jasco V-650 spectrophotometer (Jasco 
Corporation, Tokyo, Japan) and Nanodrop 1000 Spectro-
photometer (ThermoFisher); nanoparticle size distribu-
tions and zeta potential were measured using a dynamic 
light scattering Malvern Nano Zetasizer, with a 633 nm 
laser diode, from Proteomass–Bioscope facility (Capar-
ica, Portugal). Pore size distribution and surface areas 
were determined by  N2 adsorption/desorption at 77 K, 
in a Micromeritics ASAP 2010 (Micrometrics Instrument 
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Corporation, Norcross, USA) (Accelerated Surface Area 
and Porosimetry), at the Laboratory of Analysis from 
FCT—UNL. Specific surface areas  (SBET) pore volume were 
estimated using Brunauer Emmett and Teller (BET) and 
Barrett-Joyner-Halenda (BJH) methods. Infrared spectra 
(IR) were collected on a PerkinElmer Spectrum Two spec-
trometer, FTIR-ATR (Perkin Elmer Inc., Llantrisant, UK) and 
X-ray Diffraction (XRD) spectra on a RIGAKU MiniFlex II 
X-ray diffractometer, equipped with a Cu-Kα source at 
30 kV/15 mA, between 2º and 80º, at the Laboratory of 
Analysis from FCT-UNL.
Bacterial suspensions’ turbidity was adjusted with the 
aid of a DEN-1B McFarland Densiometer (Grant-bio) and 
quantified in a UV–Vis CLARIOstar spectrophotometer 
(BMG Labtech). During antibacterial assays, asepsis was 
ensured using a laminar flux chamber Steril—VBH. Incuba-
tions were performed within a Mermmet Incubator B50. 
Diffusion assays were performed in sterile paper disks with 
a diameter of 6 mm, bought at Bacto disks, and microdi-
lution assays in sterile 96-well plates, bought at Greiner 
Bio-One.
SEM images were obtained in a Quanta 650 FEG oper-
ating between 5 and 30 kV and 3.6 × 10−4 Pa of vacuum 
in the chamber. Transmission electron microscopy (TEM) 
images were obtained in a JEOL JEM-2100-HT operating 
at 200 kV, TEM images were collected using a “OneView” 
4 k × 4 k CCD camera.
2.2  Synthesis of gold–silica mesoporous 
nanoparticles (Au@MNs)
Gold nanoparticles (AuNPs) were synthesised following 
the traditional Turkevich method for the production of 
20 nm AuNPs [20, 21]. 4.9 mg of  HAuCl4 were dissolved 
in DI MiliQ water and placed under reflux for approx. 
30 min. Separately, 1.25 mL of a 10 mg/mL sodium citrate 
tribasic aqueous solution was prepared and poured onto 
the reaction pot and left to stir for an additional 15 min 
under reflux. Heating was kept until a deep wine-red col-
our was obtained. Citrate-capped AuNPs were cooled at 
room temperature and stored at 4 °C. For the growth of 
a mesoporous silica shell [18, 22], 6.25 mL of AuNP col-
loid (9.2 × 1011 particles/mL) were mixed with 10 mL of a 
15 mg/mL CTAB aqueous solution and stirred for 30 min 
at 50 °C. In this order, 30 mL of DI MiliQ water, 10 mL of EG 
and 0.7 mL of a 1 M NaOH aqueous solution were poured 
into the reaction pot and vigorously stirred for 30 min at 
80 °C. Then, 750 μL of TEOS were dropwisely added to the 
reaction mixture and stirred for 2 h at 80 °C. The resulting 
Au@MNs material was centrifuged (8.000 rpm, 10 min), 
washed three times with MeOH and dried at open-air 
conditions.
Blank mesoporous silica nanoparticles (MNs) were 
obtained following the same protocol, without the addition 
of citrate-capped AuNPs. For template removal, the Au@MNs 
and MNs were resuspended in 20 mL of a 30 mg/mL ammo-
nium nitrate methanolic solution and stirred for 1 h at 60 °C, 
followed by centrifugation and washing in MeOH. This pro-
cess was repeated twice and confirmed by IR spectroscopy 
for both materials.
2.3  Loading and release trials
Amoxicillin and ofloxacin were loaded, separately, into the 
pores of MNs and Au@MNs. Briefly, for ofloxacin, 50 mg 
of each material were resuspended in 1 mL of DMSO and 
mixed with 1 mL of a suspension of the antibiotic (10 mg/
mL), in DMSO. Amoxiciillin loading followed the same pro-
cedure but in water. Reaction mixtures were let to stir for 
24 h at 20 °C. After 24 h, 3 mL of EtOH were added to the 
reaction pots to stop the loading process and the product 
centrifuged (8.000 rpm, 5 min). The loaded NPs (Amox@
MNs, Oflox@MNs, Amox@Au@MNs and Oflox@Au@MNs) 
were washed several times with EtOH. Loading yields (L%) 
and loading capacities (LC) were determined by UV–vis 
spectroscopic quantification and mass balances (Eqs. 1 
and 2), in triplicates, at 271 nm (ε = 871.9 M−1 cm−1) and 
292 nm (ε = 36543.6 M−1 cm−1) for amoxicillin and ofloxa-
cin, respectively.
where mai (mg) is the initial amount of the antibiotic, mae 
(mg) the amount of antibiotic in the supernatant, and mNPs 
(mg) the mass of MNs or Au@MNs.
Release profiles were performed for all materials and 
measured in a Nanodrop 1000 Spectrophotometer. Briefly, 
4 mg of each material were resuspended in 2 mL of DMSO 
and stirred at 37 °C. 0.5 mL aliquots of each reaction pot 
were collected after 30 min, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h, 
48  h, 72  h and 96  h (4  days), centrifuged and quanti-
fied by UV–vis spectroscopy. Amoxicillin was quantified 
at 276 nm (ε = 141.7 M−1 cm−1) and ofloxacin at 292 nm 
(ε = 2825.8 M−1 cm−1). The same volume was, then, poured 
back into the reaction pot. The total amount of released 
antibiotics was determined by mass balance and their 
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where Mt is the absolute cumulative amount of released 
antibiotic at time t, M∞ is the total amount of antibiotic 
in MNs or Au@MNs at equilibrium, k is the diffusion coef-
ficient that incorporates structural and geometric charac-
teristics of each material, and n is the release parameter 
that determines the specific transport mechanism [23].
2.4  Antibacterial activity assays
The antibacterial activity of the synthesised nanopar-
ticles was assayed against both Gram-negative bacte-
ria—Escherichia coli (ATCC® 8739™) and Pseudomonas 
aeruginosa (ATCC® 9027™)—and Gram-positive bacte-
ria—Staphylococcus aureus (ATCC® 6538™), methicillin-
resistant Staphylococcus aureus (ATCC® 33591™) (MRSA) 
(see Table 1). Bacteria were kept frozen at − 70 °C in broth 
containing glycerol (15% v/v).
All nanoparticle powders and antibiotics were sus-
pended in DMSO to concentrations of 8 mg/mL and 1 mg/
mL, respectively (Table 2).
Initially, antibacterial activity was assayed by the agar 
diffusion method proposed by Kirby-Bauer [32]. Frozen 
microorganisms were initially inoculated in TSA and incu-
bated overnight at 35 ± 2 °C. Isolated colonies were trans-
ferred to saline medium (NaCl, 0.85% m/v) and the turbid-
ity of the suspension was adjusted to 0.5 on the McFarland 
scale (approx. 1.5 × 108 CFU/mL) [19]. Then, with a sterile 
swab, bacteria suspensions were spread on the surface of 
MHA Petri dishes, onto which sterile paper disks were set. 
Each disk was carefully loaded with 10 μL of each sample 
suspension and the plates were incubated, in the dark, 
for 24 h at 35 ± 2 °C. Antibacterial activity was evaluated, 
in duplicates, by measuring the diameter of the growth 
inhibition zone around the sterile paper disks, compared 
with those of controls. Solvent-loaded sterile paper disks 
were used as negative control.
To evaluate and quantify the bactericidal and bacte-
riostatic effects of the tested nanocomposites, all sam-
ples were assayed by the broth microdilution method in 
96-well microplate. Briefly, two-fold serial dilutions of each 
sample and controls were prepared in sterile MHB to a final 
volume of 100 μL per well. Then, each well was inoculated 
with the previously prepared bacteria suspensions. The 
microplates were incubated, in the dark, at 35 ± 2 °C for 
24 h. Free antibiotics, MNs and Au@MNs incubated in the 
presence of bacteria were used as positive controls, while 
bacteria incubated in the absence of NPs were used as 
negative controls. NPs and antibiotics incubated in the 
absence of bacteria were used as sterile controls. Each 
sample was tested in duplicate.
Upon the appointed time, an aliquot of each well was 
spread onto TSA Petri dishes and incubated in the dark, 
for an additional 24 h at 35 ± 2 °C. All 96-well plates were 
then analysed, with each well’s turbidity being observed 
at both naked-eye and in a 96-well plate ClarioStar spec-
trophotometer, at 600 nm. The obtained results were com-
pared with those obtained after the 24 h-incubated TSA 
Petri dishes. A minimum inhibitory concentration (MIC) 
was considered for a reduction in turbidity/viability of 
approx. 50%, and a minimum bactericidal concentration 
Table 1  Bacterial strains specifications
ATCC American Type Culture Collection
Strain Relevant phenotype Ref.
E. coli ATCC 8739 Gram-negative; ofloxacin sensitive [24, 25]
P. aeruginosa ATCC 9027 Gram-negative; amoxicillin resistant, ofloxacin sensitive [26, 27]
S. aureus ATCC 6538 Gram-positive, methicillin sensitive, ofloxacin sensitive [28, 29]
S. aureus ATCC 33591 (MRSA) Gram-positive, methicillin/amoxicillin resistant, ofloxacin sensitive [30, 31]
Table 2  Summary of all tested 
nanoparticles, free antibiotics 
and controls, with their stock 
concentrations
Particles ID m (mg) VDMSO (mL) []stock (mg/mL) mDrug (ug) []Drug (mg/mL)
MNs 1 4.00 0.5 8.00 – –
Au@MNs 2 4.00 0.5 8.00 – –
Oflox@MNs 3 4.00 0.5 8.00 221.9 0.4
Amox@MNs 4 4.00 0.5 8.00 491.0 1.0
Oflox@Au@MNs 5 4.00 0.5 8.00 165.7 0.3
Amox@Au@MNs 6 4.00 0.5 8.00 563.4 1.1
Amox free 7 1.00 1.0 1.00 – –
Oflox free 8 1.00 1.0 1.00 – –
DMSO 9 – 1.0 – – –
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(MBC) for a reduction in 99%, when compared to that of 
the controls [33].
3  Results and discussion
3.1  Synthesis of Gold@mesoporous silica 
nanoparticles and characterisation
Gold nanoparticles (AuNP) were obtained by the Turk-
evich method, leading to the synthesis of citrate-capped 
AuNPs, that were initially characterised by UV–Vis absorp-
tion spectroscopy and Dynamic Light Scattering (DLS) 
techniques for the determination of shape, size and zeta 
potential. The as-synthesised deep-red coloured AuNPs (50 
μL) were diluted in 2.95 mL of MiliQ water (pH = 7.0), giv-
ing place to a light-red dispersion with a typical plasmonic 
band in its absorption spectra at ca. 525 nm, character-
istic of sphere-like dispersed AuNPs (Figure S1) [21, 34]. 
Their average hydrodynamic diameter (HD), polydisper-
sion index (PDI) and zeta potential (ζ) were of 27 ± 5 nm, 
0.28 ± 0.06 and − 30 ± 4 mV (for n replicates, with n = 8), 
confirming not only their high stability but also the effec-
tive capping of AuNPs surface with citrate molecules. 
Obtained HDs are also according to those stated in lit-
erature for the same synthetic methodology [21, 35]. The 
final gold concentration in AuNPs purified dispersions was 
obtained by ICP, with [Au] = 8.24 × 10−4 M corresponding to 
an average AuNPs concentration of 9.2 × 1011 particles/mL.
Gold mesoporous nanoparticles (Au@MNs) were 
obtained through the growth of a silica shell by a well-
established and reported Stöber method for the synthe-
sis of MCM-41 [18, 36, 37]. Here, TEOS was used as silica 
source, CTAB as a cationic templating surfactant, ethylene 
glycol as stabiliser and NaOH as reducing and morphologi-
cal agent. MCM-41 mesoporous silica nanoparticles (MNs) 
produced in the absence of gold cores were used as con-
trol for all experiments. Both nanosystems were obtained 
in the form of dry powders and were Fig. 1 Top | Charac-
terization of Au@MNs nanoparticles: (A) TEM image of Au@
MNs—inset: close up on single Au@MNs (scale 69 nm). 
Size distribution histograms (for a population of N = 50) 
of (B) Au@MNs and (C) Au-cores. Characteristic type-IV  N2 
isotherms of mesoporous (D) MNs and (E) Au@MNs. Bot-
tom | Summary of MNs and Au@MNs physical properties, 
obtained from the analysis of TEM images and BET and BJH 
models application in physisorption assays characterised 
by DLS, FTIR, XRD TEM, SEM, ICP and  N2 adsorption–des-
orption isotherms (Figs. 1, 2).
MNs nanoparticles had their HD and water sta-
bility determined by DLS assays (HD = 443 ± 19  nm, 
PDI = 0.45 ± 0.09 and ζ = -21 ± 0.2 mV), showing similar 
results to those already reported for the same system, in 
the same conditions [37]. The successful production of 
silica nanoparticles was validated by their FTIR and XRD 
spectra. The presence of characteristic Si–O–Si (1225 cm−1, 
1065  cm−1, 445  cm−1), Si–O (965  cm−1, 795  cm−1) and 
Si–OH (3388 cm−1, 1645 cm−1) vibrations in the obtained 
FTIR spectra confirm the presence of a silica matrix with 
surface H-bonded silanols (Figure S2). Its corresponding 
XRD pattern revealed a broad wave packet at ca. 20º–30º, 
arising from the formation of a predominant amorphous 
silica phase in MNs nanoparticles, and well-defined diffrac-
tion peaks at 2.30º, 3.86º, 4.42º and 5.86º, corresponding 
to (100), (110), (200), (210) diffraction planes, respectively 
(Figure S3). The presence of these planes is typically associ-
ated with highly-ordered hexagonal mesoporous MCM-41 
structures [38–40].
A high mesoporosity was confirmed by  N2 adsorp-
tion–desorption type IV isotherms, with an accentuated 
adsorption step behaviour at p/p0 ca. 0.30–0.35 (Fig. 3e). 
Surface area, porous volume and pore diameter were 
assessed through Brunauer Emmett and Teller (BET) and 
Barrett-Joyner-Halenda (BJH) methods, with values of 
940.22 m2/g, 0.884 cm3/g and 34.5 Å, respectively.
Au@MNs nanoparticles were successfully obtained 
and showed excellent water dispersibility and stability, 
with HDs of about 333 ± 4 nm, for PDI = 0.16 ± 0.01 and 
ζ = -39 ± 1  mV. Total template removal was confirmed 
by FTIR spectra of the nanocomposite through the loss 
of the typical strong C-H stretching between 2900 and 
3000  cm−1 (Figure S2). However, it should be noted 
that citrate distinct peaks at ca. 2970 cm−1, 1730 cm−1, 
1390 cm−1, 1230 cm−1 and 880 cm−1 are yet visible, hint-
ing the existence of sodium citrate anhydrous-like species 
and consequently an effective encapsulation of citrate-
capped AuNPs. Silica shell growth was also confirmed 
through FTIR spectroscopy, with characteristic Si–O-Si 
(1068 cm−1, 445 cm−1), Si–O (965 cm−1, 799 cm−1) and 
Si–OH (3337 cm−1, 1641 cm−1) stretchings and bendings 
displayed in Au@MNs FTIR spectra. Similar to MNs, and 
again confirming the presence of an ordered mesoporous 
and amorphous silica shell, Au@MNs’ XRD pattern showed 
a broad signal at ca. 20º–30º along with well-defined peaks 
2.20º and 3.80º, corresponding to Si(100) and Si(110) 
planes, respectively. Interestingly, weak but defined peaks 
at 38.18º, 44.28º, 64.64º and 77.94º match those previously 
reported in literature for Au-silica nanocomposites [41, 42], 
corresponding to Au(111), Au(200), Au(220) and Au(311) 
planes, respectively (Fig. 2).
TEM images confirmed what above-mentioned tech-
niques already hinted for, showing highly porous well-
defined spherical nanoparticles centred by a single AuNP 
core, with average diameters of 213 ± 5 nm and 26 ± 3 nm, 
respectively (Fig. 1a–c and Figure S4).  N2 adsorption–des-
orption assays developed type IV isotherms, typical of 
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mesoporous materials, with surface area, porous volume 
and pore size of 1028.13 m2/g, 1.111 cm3/g and 33.8 Å, 
respectively (Fig. 1d). Note that, the increase in surface 
area and porous volume is consequence of Au@MNs larger 
particle diameter. Au content in Au@MNs was determined 
by ICP, amounting to 6.83 mg of Au per gram of nanopar-
ticles. SEM micrographs of MNs and Au@MNs showed a 
particle size of 193 ± 27 nm and 194 ± 23 nm, respectively.
3.2  Antibiotics loading and release studies
The physical adsorption of amoxicillin and ofloxacin 
into nanoparticles (i.e. MNs and Au@MNs) pores was 
achieved in MiliQ water (pH 7), or DMSO, respectively. 
The loading solvents were selected to ensure good solu-
bility and homogeneity of each antibiotic, and nanopar-
ticles, during the loading process. Both antibiotic load-
ings were evaluated after 24 h incubations, at 20 °C, and 
upon each wash’s supernatant quantification by UV–vis 
absorbance spectroscopy. Amoxicillin and ofloxacin 
solutions of 1 × 10−5  M, prepared in MiliQ water and 
DMSO respectively, were used as standards. Their spectra 
were collected at 20 °C, with absorption maxima cen-
tred at 271 nm, for amoxicillin, and 292 nm, for ofloxacin. 
The latter also presenting a shoulder at 330 nm (Fig. 3a). 







S URFACE A REA
BET Surface area 940.22 m2/g
BJH Adsorpt ion cumulative surface area of pores
between 17 Å and 3 000 Å diameter 1028.4 m²/g
BJH Desorpt ion cumulative surface area of pores
between 17 Å and 3 000 Å diameter 1021.1 m²/g
PORE VOLUME
BJH Adsorption cumulative volume of pores
between 17 Å and 3 000 Å diameter 0.884 cm³/g
BJH Desorption cumulative volume of pores
between 17 Å and 3 000 Å diameter 0.881 cm³/g
PORE SIZE
BJH Adsorption average pore diameter 34.4 Å
BJH Desorption average pore diameter 34.5 Å
Au@MNs
PA RTICLE S IZE (TEM)
Particle diameter [AVG ± STDV] 212 ± 9 nm
S URFACE A REA
BET Surface area 1028.13 m2/g
BJH A dsorption cumulative surface area of pores
between 17 Å and 3 000 Å diameter 1288.5 m²/g
BJH Desorption cumulative surface area of pores
between 17 Å and 3 000 Å diameter 1313.9m²/g
PORE VOLUME
BJH A dsorpt ion cumulative volume of pores
between 17 Å and 3 000 Å diameter 1.087cm³/g
BJH Desorpt ion cumulative volume of pores
between 17 Å and 3 000 Å diameter 1.111 cm³/g
PORE SIZE
BJH Adsorption average pore diameter 33.7 Å
BJH Desorption average pore diameter 33.8 Å
Fig. 1  Top—characterization of Au@MNs nanoparticles: a TEM 
image of Au@MNs—inset: close up on single Au@MNs (scale 
69  nm). Size distribution histograms (for a population of N = 50) 
of b Au@MNs and c Au-cores. Characteristic type-IV  N2 isotherms 
of mesoporous d MNs and e Au@MNs. Bottom—summary of MNs 
and Au@MNs physical properties, obtained from the analysis of 
TEM images and BET and BJH models application in physisorption 
assays
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amoxicillin encapsulation reaching L% values of 62% 
(i.e. LC = 122.75 mg/g) and 70% (i.e. LC = 140.85 mg/g), 
for MNs and Au@MNs respectively. Conversely, ofloxacin 
loadings reached L% values of 31% (i.e. LC = 62.32 mg/g) 
and 35% (i.e. LC = 42.18 mg/g), for MNs and Au@MNs 
respectively (Fig. 3b).
The systems displayed great loading capacity match-
ing already published silica-based materials for the same 
antibiotics, some of which had to undergo a previous 
organofunctionalisation process of their pores and sur-
faces to attain their loading levels (Table 3). Amox@Au@
MNs showed L% and LC values competitive with those 
obtained for surface-modified mesoporous silicas; while 
their Au-free counterpart (Amox@MNs) bested, by far, 
any as-synthesised mesoporous silica material reported 
in literature. Here in produced ofloxacin-loaded materi-
als, exhibited great encapsulation appetency, reproducing 
similar results to those of Nuti et al. [18]. The scarceness 
of reported ofloxacin-loaded mesoporous silica nanoma-
terials, represents an opportunity for the introduction of 
such materials in bacteria eradication while aiming for a 
reduction in prescribed ofloxacin quantities.
Amoxicillin and ofloxacin loaded materials were also 
characterised by DLS measurement of their size and zeta 
potential. Amox@Au@MNs and Oflox@Au@MNs showing 
larger HDs (454 ± 24 nm and 557 ± 10 nm, respectively) and 
lower ζ (− 17 ± 1 mV and − 19 ± 1 mV, respectively) can be 
attributed to an efficient functionalisation of pores and 
surfaces, although with a destabilising effect.
Release assays were performed in DMSO at 37 °C, as 
all samples were dispersed in DMSO for 1 h, prior to its 
application in antimicrobial activity assays. The release 
assay was followed by absorbance measurements of all 
supernatants, at each drug maximum, for 5 days. Amoxicil-
lin release maxima for MNs and Au@MNs were of ca. 15% 
and 10% (i.e. 19 mg/g and 15 mg/g), respectively (Fig. 3c), 
while ofloxacin released maxima were of ca. 14% and 12% 
(i.e. 9 mg/g and 7 mg/g) (Fig. 3d). Such results indicate 
a delaying effect of Au-cores presence over antibiotics 
release, which was confirmed by fitting the collected data 
to the semi-empirical Korsmeyer-Peppas. Through a lin-
earization of Eq. 3 we have,
And fitting to the already treated and logaritmised data, 
it was possible to determine both n and k  (h−n) for all anti-
biotic-nanoparticles systems, summarised in Table 4 (see 
figure S5). With all systems presenting a spherical shape 
and having values of n < 0.43, it can be concluded that, 
as expected, we are working with non-swellable matrixes 
where diffusion phenomena rule antibiotics mass transfer, 
from nanoparticles to the surrounding medium. In these 
cases, diffusion follows a quasi-fickian model with diffu-
sion rates as functions of time, for k values defined by t−n 
[49–51].
3.3  Antibacterial activity assays
The antibacterial activity of each system was initially 
tested in sterile paper disks, which were placed in contact 
with E. coli, P. aeruginosa, S. aureus and MRSA cultures. All 
nanoparticles were loaded at a concentration of 8.0  mgNP/
mL, corresponding to: 1.0  mgAmox/mL and 1.1  mgAmox/mL 
for Amox@MNs and Amox@Au@MNs, respectively; and 0.4 
 mgOflox/mL and 0.3  mgOflox/mL for Oflox@MNs and Oflox@
Au@MNs. The formation of growth inhibition zones and 
their diameters are evidence of each formulation’s anti-
bacterial activity, when compared to those formed, or not, 
in the presence of free amoxicillin, free ofloxacin and their 




= log k + n ⋅ log t
PEAK 2θ (º) I (cps) PLANE dhkl (Å) MATERIAL
1 2.20 9008 (100) 40.12
SiO22 3.8 3072 (110) 22.52
3 20-(23)-30 927 (200) -
4 38.18 477 (111) -
Au
5 44.28 322 (200) -
6 64.64 240 (220) -
7 77.94 191 (311) -
Fig. 2  Left—Au@MNs XRD pattern for 2θ angles between 2º and 
80º—inset: close up on Au typical peaks for angles between 30º 
and 80º. Right—summary on the registered peaks and associated 
intensities, 2θ angles, atomic planes, interplanar d-spacing  (dhkl) 
and type of material
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From the results displayed in Table 5, it is evident that 
most strains have a high susceptibility to ofloxacin, with all 
systems showing significant growth inhibition zones after 
incubations. This is in accordance with the information 
detailed in previous reports [52, 53], as well as ATCC and 
BacDive database [24–31, 54], where no ofloxacin resist-
ance is indicated for any of the studied strains.
Regarding amoxicillin, the methicillin-susceptible S. 
aureus strain exhibited susceptibility to all formulations 
(i.e. free antibiotics and amoxicilin-loaded NPs), confirming 
not only the presence of the antibiotic in the nanosystems, 
but also its effective delivery from the nanoparticles to the 
bacterial medium. For E. coli, an ihnibition zone of 13 mm 
was recorded around the free amoxicillin disk. However, 
with loaded-MNs and Au@MNs no measurable growth 
inhibition zones were detected, suggesting an inability 
of these nanosystems to deliver the necessary amount of 
antibiotic.
Additionally, and as expected, both MRSA and P. aer-
uginosa showed strong resistance towards amoxicillin, 
as no zones of inhibition were observed for any formu-
lation. Amoxicillin is a β-lactam antibiotic that binds to 
transpeptidase domain of penicillin-binding proteins 
(PBP) preventing peptidoglycan biosynthesis [55]. MRSA 
methicillin-resistance [3] confers them resistance to 
other β-lactam antibiotics, such as oxacillin, penicillin 
and amoxicillin [56]. This resistance results from expres-
sion of β-lactamases and of an altered form of PBP 
(encoded by mecA gene) with low affinity to β-lactam 
and higher rates of release of the bound drug [57, 58] 
On the other hand, the interaction between the induc-
ible β-lactamase AmpC and the P. aeruginosa resistance 
nodulation cell division multidrug efflux systems, lists 
this strain as one towards which amoxicillin is not effec-
tive [59].
Despite all registred zones of inhibition for antibiotic-
loaded MNs and Au@MNs systems, none exhibited diam-
eters larger than those obtained for the free antibiotics. 
This fact may derive from nanoparticles dispersibility 
issues in the sterile paper disk matrix, that did not allow 






Fig. 3  a Absorption spectra of free antibiotics at approx. 10–5  M. 
b Chemical structure of both amoxicillin and ofloxacin, and cor-
responding Loading Capacities (LC) of MNs and Au@MNs systems 
towards the same antibiotics. c Amoxicillin release profiles from 
MNs and Au@MNs, in DMSO at 37  °C, for 5  days—inset: first 6  h 
of release. d Ofloxacin release profiles from MNs and Au@MNs, in 
DMSO at 37 °C, for 5 days—inset: first 4 h of release
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for a total dispersion and transport of the antibiotics to 
bacterial media.
Broth microdilution assays were used to overcome dis-
persion issues, with each formulation (i.e. free antibiotics, 
MNs, Au@MNs, Amox@MNs, Amox@Au@MNs, Oflox@
MNs and Oflox@Au@MNs) being resuspended in DMSO to 
attain good dispersibility and homogeneity. This method 
allows not only for direct contact between nanoparticles 
and bacteria but also for greater sensibility. A gradient of 
concentrations for each formulation, ranging between ca. 
Table 3  Comparison between in-work developed materials and other already published in literature
Antibiotic Supporting material Material ID Type of interaction % L (%) LC (mg/g) Ref.
Amoxicillin SBA-15 SBA-15-x Adsorption – – [43]
SBA 15-xA 19 –
SBA-15-xM 25 –
SBA-15-xT – –
SBA-16 SBA-16 Covalent 3.2 13 [44]
SBA-16IPD 51 204
SBA-16IPDB 51 204









MCM-41 Fe3O4/SiO2/CTAB–SiO2 Adsorption – 363 [46]











MCM-41 MNs Adsorption 62 123 This work
Au@MNs 70 141




MCM-41 Si.P700 Adsorption 80 – [48]
Si-NP8 67 –
MCM-41 MNs Adsorption 31 62 This work
Au@MNs 35 42
Table 4  Semi-empirical Korsmeyer–Peppas diffusion model param-
eters upon fitting to experimental amoxicillin and ofloxacin release 
data
NP sample R2 n k (t−n)
Amox@MNs 0.9227 0.19 0.705
Amox@Au@MNs 0.9983 0.11 0.636
Oflox@MNs 0.9987 0.11 0.794
Oflox@Au@MNs 0.9989 0.13 0.847
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10–0.006 μgAntibiotic/mL (765–1 μgNPs/mL), was tested to 
assess both MIC and MBC by absorbance spectroscopic 
techniques, against E. coli ATCC 8739™, the susceptible S. 
aureus ATCC 6538™, the resistant MRSA ATCC 33591™ and 
P. aeruginosa ATCC 9027™. MIC and MBC validation was 
attained by plating on TSA plates.
No antibacterial activity was registred with MNs, Au@
MNs and DMSO, that served as controls along the whole 
experiment. It should be noted that antibiotic concen-
tration is variable, depending on each nanoparticle 
loading capacity (see Sect. 3.2. Antibiotics Loading and 
Release studies). Free antibiotics were also tested within a 
95–0.015 μgAntibiotic/mL concentration range and used as 
standards (Table 6).
Overall, amoxicillin-loaded systems followed a similar 
tendency to that observed in disk diffusion assay, having 
a more effective activity against the susceptible S. aureus 
strain, than for other bacteria. Amox@MNs and Amox@
Au@MNs MICs towards S. aureus matched their own MBCs, 
that were confirmed for concentrations of 1 μgAmox/mL 
Table 5  Summarising table with all growth inhibition zones’ average diameters
Measured lengths represent the obtained means ± an associated absolute error of 0.5 mm




d̄ Inhibition zone (mm) d̄ Inhibition zone (mm) d̄ Inhibition 
zone (mm)
d̄ Inhibition zone (mm)
MNs – 0 0 0 0
Au@MNs – 0 7 0 7
Free Amox 10.0 13 45 7 0
Amox@MNs 9.8 0 19 0 0
Amox@Au@MNs 11.3 0 15 0 0
Free Oflox 10.0 38 31 32 25
Oflox@MNs 4.4 20 19 17 9
Oflox@Au@MNs 3.3 17 17 14 8
DMSO – 0 0 0 0
Table 6  Minimum inhibitory 
concentration (MIC) and 
minimum bactericidal 
concentration (MBC) of 
DMSO, MNs, Au@MNs and the 
free antibiotics towards the 
selected bacterial strains




DMSO E. coli ATCC 8739 N/D N/D
S. aureus ATCC 6538 N/D N/D
MRSA ATCC 33591 N/D N/D
P. aeruginosa ATCC 9027 N/D N/D
MNs E. coli ATCC 8739 N/D N/D
S. aureus ATCC 6538 N/D N/D
MRSA ATCC 33591 N/D N/D
P. aeruginosa ATCC 9027 N/D N/D
Au@MNs E. coli ATCC 8739 N/D N/D
S. aureus ATCC 6538 N/D N/D
MRSA ATCC 33591 N/D N/D
P. aeruginosa ATCC 9027 N/D N/D
Free amoxicilin E. coli ATCC 8739 5 (–) 5 (–)
S. aureus ATCC 6538 0.015 (–) 0.07 (–)
MRSA ATCC 33591 N/D N/D
P. aeruginosa ATCC 9027 95 (–) N/D
Free ofloxacin E. coli ATCC 8739 0.03 (–) 0.03 (–)
S. aureus ATCC 6538 0.15 (–) 0.3 (–)
MRSA ATCC 33591 0.3 (–) 0.6 (–)
P. aeruginosa ATCC 9027 0.6 (–) 0.6 (–)
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(80 μgNPs/mL) and 3 μgAmox/mL (360 μgNPs/mL), respec-
tively. However, when compared to the obtained viability 
of the free amoxicillin formulation (Table 6), which led to 
inhibition at 0.015 μgAmox/mL and death at 0.07 μgAmox/
mL, no significant beneficial role can be assigned to the 
antibiotic decorated nanoparticles.
Within the range of tested concentrations, amoxicillin-
nanosystems were only able to inhibit E. coli and P. aer-
uginosa growth. All assayed concentrations of Amox@
MNs and Amox@Au@MNs failed to reduce both bacteria 
viabilities by 99%, pointing to MBCs at values > 765 μgNPs/
mL. The MIC of Amox@MNs, towards E. coli, was deter-
mined for a concentration of 10 μgAmox/mL (765 μgNPs/mL), 
whereas no MIC was registred for Amox@Au@MNs (MBC 
and MIC > 765 μgNPs/mL). Again, when compared to those 
obtained for the free antibiotic (Table 6) no beneficial role 
is evident. Regarding P. aeruginosa, whilst free amoxicillin 
only had a MIC at 95 μgAmox/mL, Amox@MNs and Amox@
Au@MNs displayed MICs at lower antibiotic concentra-
tions of 10 μgAmox/mL (765 μgNPs/mL) and 5 μgAmox/mL 
(765 μgNPs/mL), respectively. This result gives our nanosys-
tems a beneficial role in the reduction of prescribed anti-
biotics, with Amox@MNs and Amox@Au@MNs allowing 
for a 10-fold and a 20-fold reduction, respectively, while 
maintaining its bacteriostatic activity.
Concerning MRSA, concentrations up to 95 μgAmox/
mL of free amoxicillin failled to reduce bacteria viabilities 
by 50% (MIC and MBC > 95 μgAmox/mL) (Table 6). However, 
prominent bacteriostatic and bactericidal activity was 
observed for Amox@MNs that exhibited a MIC of 5 μgAmox/
mL (i.e. for 360 μgNPs/mL) and a MBC of 10 μgAmox/mL 
(765 μgNPs/mL). Thus, leading to not only an higher than 
20-fold decrease in needed antibiotic, but also allowing a 
circumvention of the already existing resistance. Amox@
Au@MNs, however, showed no MIC and MBC within the 
tested concentration range. All amoxicillin-based formula-
tion results are sumarised in Table 7.
As observed with free ofloxacin, both ofloxacin nano-
systems showed strong effectiveness against all bacte-
rial strains, for most tested concentrations. In general, 
Oflox@MNs performance was more stressed than that of 
its Au-based counterpart, being in line with the above 
mentioned release profiles of ofloxacin-decorated nano-
particles, where Oflox@MNs showed higher appetency 
to dispense the antibiotic than Oflox@Au@MNs.
The determined MIC and MBC of Oflox@MNs towards 
E. coli were both of 0.03 μgOflox/mL (4 μgNPs/mL), and 
identical to those obtained for free ofloxacin (Table 6). 
Oflox@Au@MNs however, were able to reduce the MIC 
by half, inducing a 50% reduction in bacteria viability 
at 0.015  μgOflox/mL (4  μgNPs/mL). A similar tendency 
was observed towards the susceptible S. aureus strain, 
with Oflox@MNs having a MIC (i.e. 0.15 μgOflox/mL for 
20 μgNPs/mL) and a MBC (i.e. 0.3 μgOflox/mL for 40 μgNPs/
mL) equal to those of the free antibiotic. The presence 
of Au cores played no beneficial role, leading instead 
to an increase of the MBC to 0.6 μgOflox/mL (170 μgNP/
mL). Regarding MRSA, whilst Oflox@Au@MNs were 
capable of decreasing the MIC to half of that obtained 
for free ofloxacin (i.e. 0.15 μgOflox/mL for 40 μgNPs/mL), 
only Oflox@MNs were able to reduce in half the MBC 
to 0.3 μgOflox/mL (40 μgNP/mL). Lastly, both Oflox@MNs 
and Oflox@Au@MNs MBCs showed no significant differ-
ences towards P. aeruginosa, when compared to that of 
the free antibiotic. The two formulations were able to 
induce a 2-fold reduction in the MIC, to concentrations 
of 0.3 μgOflox/mL (40 μgNP/mL and 80 μgNP/mL for Oflox@
MNs and Oflox@Au@MNs, respectively). A compilation of 
all ofloxacin-based formulation is displayed in Table 8.
The significant decrease in needed antibiotic is 
hypothesised to be the result of a mixed effect between 
the already reported protective role of the mesoporous 
structures over loaded drugs and antibiotics [10, 60], and 
the attaching and stressing power of MNs shells onto the 
surface of bacteria [61, 62].
It should be noted that, tested concentrations (of NPs 
and antibiotics) are three to four orders of magnitude 
lower than those tested in a sterile paper disk, highlight-
ning again the importance of direct contact between 
nanoparticles and bacteria.
Table 7  Minimum inhibitory 
concentration (MIC) and 
minimum bactericidal 
concentration (MBC) for all 
amoxicillin-based tested 
formulations, against selected 
bacterial strains






E. coli ATCC 8739 10 (765) N/D
S. aureus ATCC 6538 1 (80) 1 (80)
MRSA ATCC 33591 5 (360) 10 (765)
P. aeruginosa ATCC 9027 10 (765) N/D
Amox@Au@MNs
Amox c.a. 140.85 mg/g
E. coli ATCC 8739 N/D N/D
S. aureus ATCC 6538 3 (360) 5 (765)
MRSA ATCC 33591 N/D N/D
P. aeruginosa ATCC 9027 5 (765) N/D
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Silica-based nanoparticles that have been reported 
to efficiently bind to both Gram-negative and Gram-
positive bacteria, as all herein tested bacteria [63], and 
have already been reported to change surface roughness 
and stability, while inducing membrane stress and mem-
brane disruption (namely by the silanol groups that have 
appetency for phospholipid membrane destruction) 
[64]. Thus, an increase in membrane permeabilization 
could expedite antibiotic access and, consequentely, 
their action inside bacterial cells [65].
Particularly, in what concerns β-lactam antibiotics, 
high antibiotic concentrations could be dispensed in 
bacterial cells by nanoparticle/antibiotic combinations, 
allowing the antibiotic to act before being degraded by 
bacterial β-lactamases [66, 67]. Additionally, antibiotic 
nanosystems could inhibit the transmembrane pump 
that catalyses drug efflux from P. aeruginosa cells [67].
Moreover, the induction of MRSA resistance reversion 
by Amox@MNs could be related to MNs perturbations 
in cell envelope upon interaction with the bacteria. As 
hypothesised by Kong et al. [68], the resulting pertur-
bations in cell envelope could affect the expression of 
resistance-responsible genes, by disrupting the activity 
of sensor-inducer proteins located in cell membrane, 
which are responsible for the expression of resistance 
proteins.
Briefly, the herein synthesised formulations had a 
considerable beneficial role on the effective delivery of 
amoxicillin to the selected strains; namely, against the 
resistant S. aureus mutant, MRSA, and the well-known 
β-lactam resistant P. aeruginosas. Among its more prom-
ising results, are the significant reduction of amoxicil-
lin in future prescriptions, reducing the possibility of 
development of resistance, and Amox@MNs’ surprising 
circumvention of MRSA resistance. Ofloxacin loaded nan-
oparticles did not show as outstanding performances 
as those of their amoxicillin-loaded counterparts, being 
only able to slightly reduce ofloxacin amounts for both 
MIC and MBC.
4  Conclusions
To summarise, nanocarriers comprising of core–shell 
gold–silica based mesoporous nanoparticles (Au@MNs) 
and silica mesoporous nanoparticles (MNs) were success-
fully synthesised and fully characterised. Both nanocarriers 
revealed a spherical shape and high porosity with surface 
areas of 1028.13 m2/g and 940.22 m2/g for Au@MNs and 
MNs, respectively. The loading ability of these nanosys-
tems was evaluated towards amoxicillin and ofloxacin 
antibiotics, where high encapsulation yields of 62% (MNs) 
and 70% (Au@MNs) were achieved for amoxicillin. Amox@
MNs, Amox@Au@MNs, Oflox@MNs and Oflox@Au@MNs 
nanoformulations were tested against S. aureus, methi-
cillin-resistant S. aureus (MRSA), E. coli and P. aeruginosa 
in sterile paper disks and by broth microdilution assays. 
The best results were achieved by broth microdilutions 
assays, since this method allows a direct contact between 
nanoparticles and bacteria. Which was confirmed as cru-
cial variable. Within the range of tested concentrations, 
amoxicillin-nanosystems were able to inhibit E. coli and 
P. aeruginosa growth. From the obtained results, it is clear 
their significant and benefical role, by promoting a 10-fold 
(Amox@MNs) and a 20-fold (Amox@Au@MNs) reduction 
of needed amoxicillin to inhibed P. aeruginosa. Regarding 
MRSA, not only a 20-fold decrease in amoxicillin MIC was 
obtanined for Amox@MNs, but also a full circumvenction 
of the resistance was possible at a MBC of 5 μAmoxg/mL. 
Ofloxacin loaded nanoparticles were also able to reduce 
ofloxacin amounts in both MIC and MBC, although less 
significantly. The above obtained results, aligned with the 
straighforwardness and cheapness of the reported base 
materials, may place these novel formulation as a possible 
and determining therapeutic tools to tackle AMR and its 
development.
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